Dear Mr. Fitzgerald:

Please refer to your supplemental new drug applications dated June 11, 2010, and received June 11, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA Inhalation Aerosol (fluticasone propionate and salmeterol xinafoate), and Serevent Diskus (salmeterol xinafoate inhalation powder).

Reference is also made to our letter dated February 18, 2010, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for all long-acting beta-agonist (LABA) products. This information pertains to the risk of serious asthma outcomes (asthma-related death, intubations, and hospitalizations) with the use of the class of the LABA, of which Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder), Advair HFA Inhalation Aerosol (fluticasone propionate and salmeterol xinafoate), and Serevent Diskus (salmeterol xinafoate inhalation powder) are members.

Reference is also made to our faxes dated May 6, and 13, 2010, receipt of your May 18, 2010 submission, and our Safety Labeling Change Order Letter dated June 2, 2010.

These supplemental new drug applications provide for revisions to the Medication Guide and package insert for Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder) and Advair HFA Inhalation Aerosol (fluticasone propionate and salmeterol xinafoate), to include changes to the BOXED WARNING, INDICATIONS AND USAGE, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, and PATIENT COUNSELING INFORMATION sections of the Package Insert and the Medication Guide.

The supplemental application for Serevent Diskus (salmeterol xinafoate inhalation powder) provides for revisions to the Medication Guide and package insert to include changes to the BOXED WARNING, CLINICAL TRIALS, INDICATIONS AND USAGE,
CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the Package Insert and the Medication Guide.

We have completed our review of these supplemental applications. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Your approved Medication Guides will become part of the REMS in \( \text{(b) (4)} \) for Advair Diskus, \( \text{(b) (4)} \) for Advair HFA, and \( \text{(b) (4)} \) for Serevent Diskus.

CONTENT OF LABELING

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, and text for the Medication Guide) submitted on June 11, 2010, and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in these supplements, including any new safety information [21 CFR 314.70(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

As required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about these drug products (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to the respective NDAs, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch  
Food and Drug Administration  
Suite 12B-05  
5600 Fishers Lane  
Rockville, MD 20857

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Eunice Chung, Regulatory Project Manager, at (301) 796-4006.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary, Allergy, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-21077</td>
<td>SUPPL-42</td>
<td>GLAXOSMITHKLINE</td>
<td>ADVAIR DISKUS(SALMETEROL/FLUTICASONE PRO</td>
</tr>
<tr>
<td>NDA-21254</td>
<td>SUPPL-13</td>
<td>GLAXOSMITHKLINE</td>
<td>ADVAIR HFA(FLUTICASONE PROPIONATE/SALMET</td>
</tr>
<tr>
<td>NDA-20692</td>
<td>SUPPL-36</td>
<td>GLAXO GROUP LTD DBA GLAXOSMITHKLINE</td>
<td>SEREVENT DISKUS 50MCG INHALATION POWDER</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BADRUL A CHOWDHURY
06/25/2010